|
Sandoz strengthens pipeline by entering into agreement for biosimilar bevacizumab, a key oncology medicine
|
08 September 2021 |
|
Novartis and Hewlett Packard Enterprise join forces to advance Novartis global health efforts
|
23 June 2021 |
|
Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19
|
31 May 2021 |
|
Novartis reaches milestone delivery of 1 billion courses of antimalarial treatment
|
19 May 2021 |
|
Novartis signs initial agreement to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient for Roche's Actemra/RoActemra®
|
29 April 2021 |
|
Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate
|
05 March 2021 |
|
Novartis signs initial agreement to provide manufacturing capacity for Pfizer-BioNTech COVID-19 vaccine
|
10 February 2021 |
|
Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19
|
14 December 2020 |
|
Novartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)
|
06 November 2020 |
|
Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19
|
03 November 2020 |